Related Experiment Videos
[Treatment of migraine attacks]
A Pradalier1, G Baudesson, A Delage
1Service de médecine interne IV et centre migraine et céphalées, hôpital Louis-Mourier, Colombes, France.
Pathologie-Biologie
|November 10, 2000
Summary
This review covers drug treatments for migraine attacks, including non-steroidal anti-inflammatory drugs (NSAIDs), ergot derivatives, and triptans. It details their properties, uses, and contraindications for effective migraine headache management.
Area of Science:
- Pharmacology
- Neurology
- Clinical Therapeutics
Context:
- Migraine headaches represent a significant neurological disorder impacting millions globally.
- Effective acute management of migraine attacks is crucial for patient quality of life.
- A variety of pharmacological agents are available for migraine treatment.
Purpose:
- To review and synthesize findings from controlled studies on key drug classes used for acute migraine management.
- To provide an overview of the properties, indications, and contraindications of NSAIDs, ergot derivatives, and triptans.
- To guide clinical decision-making in the selection of appropriate migraine attack therapies.
Summary:
- Non-steroidal anti-inflammatory drugs (NSAIDs) offer a first-line treatment option for mild to moderate migraine attacks.
- Rye ergot derivatives, while historically significant, have a more limited role due to side effect profiles.
- Triptans represent a targeted therapy for moderate to severe migraine attacks, acting on serotonin receptors.
Impact:
- This review aids clinicians in selecting optimal pharmacotherapy for individual migraine patients.
- Understanding drug profiles enhances safe and effective migraine management strategies.
- Informs future research directions in the development of novel migraine treatments.